Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654 1675
This examiner grants 80% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17926479 | METHODS FOR TREATING PLASMA PROTEIN IMBALANCES OR DEPLETION | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18345975 | BOTULINUM NEUROTOXIN-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | Final Rejection | REGENERON PHARMACEUTICALS, INC. |
| 18047135 | VIP Antagonists and Uses in Treating Cancer | Non-Final OA | Georgia Tech Research Corporation |
| 17779072 | COMPOSITIONS AND METHODS FOR USE IN TYPE 1 DIABETES | Non-Final OA | The Research Foundation for The State University of New York |
| 17757058 | RETINA REGENERATION THROUGH EPIGENETICS MANIPULATION | Non-Final OA | Baylor College of Medicine |
| 17761854 | BACTERIOCINS FOR CONTROL OF SALMONELLA ENTERICA | Final Rejection | Nomad Bioscience GmbH |
| 18031958 | USE OF TRIGONAL AGONIST HAVING ACTIVITIES TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS IN TREATMENT OF SEQUELAE FOLLOWING RESPIRATORY INFECTIOUS DISEASES | Non-Final OA | HANMI PHARM. CO., LTD. |
| 18498452 | BRANCHED PEPTIDES FOR ENZYMATIC ASSEMBLY AND MITOCHONDRIA DRUG DELIVERY | Final Rejection | BRANDEIS UNIVERSITY |
| 17482273 | METHODS FOR TREATING SEVERE ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R INHIBITOR | Final Rejection | SANOFI BIOTECHNOLOGY |
| 18150983 | METHOD OF PURIFYING ALBUMIN-FUSION PROTEINS | Non-Final OA | MedImmune, LLC |
| 18035707 | A COMPOSITION COMPRISING EXTRA-CELLULAR VESICLES FROM MESENCHYMAL STEM CELLS AND ALPHA-1 ANTITRYPSIN FOR THE TREATMENT OF VIRAL INFECTIONS | Non-Final OA | AATEC MEDICAL GMBH |
| 18251652 | POLYPEPTIDES FOR USE IN THE TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | Non-Final OA | IMMUNE SYSTEM KEY LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy